Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026)
Viatris (VTRS) posted Depreciation & Amortization (CF) of $672.3 million for Q2 2026, down 0.56% on a QoQ basis from $676.1 million in Q1 2026, and down 0.88% year-over-year from $678.3 million in Q2 2025.
Analysis
Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Viatris has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $672.3 million in Q2 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 0.88% year-over-year to $672.3 million in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 1.62% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, down 3.28% from the prior year.
- Depreciation & Amortization (CF) was $672.3 million for Q2 2026 at Viatris, down from $676.1 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $869.8 million in Q4 2022, with the low at $644.4 million in Q4 2023.
- Average Depreciation & Amortization (CF) over 5 years is $711.6 million, with a median of $689.8 million recorded in 2024.
- The largest YoY upside for Depreciation & Amortization (CF) was 16.0% in 2022 against a maximum downside of 48.26% in 2022.
- Over 5 years, Depreciation & Amortization (CF) stood at $869.8 million in 2022, then dropped by 25.91% to $644.4 million in 2023, then advanced by 15.8% to $746.2 million in 2024, then advanced by 2.76% to $766.8 million in 2025, then declined by 12.32% to $672.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $672.3 million (Q2 2026), $676.1 million (Q1 2026), and $766.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 241.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 672.30 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 56.74 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 281.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 10.33 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 19.64 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 672.30 Mn |
| Mar 31, 2026 | 676.10 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Mar 31, 2024 | 691.00 Mn |
| Dec 31, 2023 | 644.40 Mn |
| Sep 30, 2023 | 679.40 Mn |
| Jun 30, 2023 | 686.70 Mn |
| Mar 31, 2023 | 730.00 Mn |
| Dec 31, 2022 | 869.80 Mn |
| Sep 30, 2022 | 699.50 Mn |
| Jun 30, 2022 | 722.30 Mn |
| Mar 31, 2022 | 736.00 Mn |
| Dec 31, 2021 | 749.80 Mn |
| Sep 30, 2021 | 1.02 Bn |